Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10134
Title: Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Authors: Kelly, Marcus P;Lee, Fook-Thean;Smyth, Fiona E;Brechbiel, Martin W;Scott, Andrew M
Affiliation: Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria 3084, Australia.
Issue Date: 1-Apr-2006
Citation: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine; 47(4): 716-25
Abstract: Radioimmunotherapy (RIT) of solid tumor is often limited in efficacy because of restrictions in achieved tumor dose. In an effort to overcome this, the combination of RIT with other therapeutic modalities was investigated in an animal model of breast carcinoma. The rationale for this combined-modality RIT (CMRIT) was to increase the therapeutic efficacy of RIT through the use of paclitaxel to arrest cells in the radiosensitive G(2)/M phase of the cell cycle.In this study, the biodistribution and therapeutic efficacy of (90)Y-radiolabeled humanized anti-Lewis Y hu3S193 monoclonal antibody ((90)Y-hu3S193) RIT in combination with paclitaxel chemotherapy was explored in a Lewis Y-expressing MCF-7 tumor xenografted BALB/c nude mouse model of breast cancer.Biodistribution studies demonstrated excellent tumor targeting and limited normal tissue uptake by (90)Y-hu3S193. A therapeutic study with established tumors assessed (90)Y-hu3S193 as a single agent and demonstrated significant antitumor effects in all animals receiving a single intravenous 1.85 or 3.70 MBq dose of this treatment compared with phosphate-buffered saline placebo controls (P = 0.0008 vs. P < 0.0001). Complete responses were observed in all animals in the 3.70 MBq study arm for the duration of the study. Single-dose (90)Y-hu3S193 plus paclitaxel (600 microg) CMRIT displayed improved efficacy over single-modality therapies, with a significant difference (P < 0.0001) between the mean percentage change in tumor volume in mice receiving 0.46 MBq (90)Y-hu3S193 alone and when combined with 600 mug paclitaxel.The significant efficacy of (90)Y-hu3S193 and paclitaxel CMRIT at low radiation doses in this model of breast carcinoma indicates its therapeutic potential and warrants further investigation into this promising therapeutic approach.
Internal ID Number: 16595507
URI: http://ahro.austin.org.au/austinjspui/handle/1/10134
URL: http://www.ncbi.nlm.nih.gov/pubmed/16595507
Type: Journal Article
Subjects: Animals
Antibodies, Monoclonal.pharmacokinetics.therapeutic use
Antineoplastic Agents, Phytogenic.therapeutic use
Breast Neoplasms.drug therapy.radiotherapy
Cell Line, Tumor
Combined Modality Therapy
Female
Humans
Lewis Blood-Group System.immunology
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Transplantation
Neoplasms, Experimental.drug therapy.radiotherapy
Paclitaxel.therapeutic use
Radioimmunotherapy
Radiopharmaceuticals.pharmacokinetics.therapeutic use
Tissue Distribution
Transplantation, Heterologous
Yttrium Radioisotopes
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.